|
|
|
| Skin test and economic analysis of cephalosporins in our hospital |
| XU Bingfa WU Along HUANG Jian |
| Department of Pharmacy, Third Hospital Affiliated to Anhui Medical University, Anhui Province, Hefei 230061, China |
|
|
|
Abstract Objective To conduct an economic analysis on the cost of skin test and to provide a basis for the management of skin test of cephalosporins. Methods By using the clinical information system of Third Hospital Affiliated to Anhui Medical University (hereinafter referred to as “our hospital”), the basic information, skin test results and and the incidence of adverse drug reaction (ADR) among inpatients who received cephalosporin injections in our hospital from January 2018 to December 2019 were counted, and the positive rate of skin test, skin test related costs and the reduced cost of allergic reactions according to the skin test were calculated. Results The total number of cephalosporin skin test cases was 36 784, and the positive rate of skin test was 2.63%. The positive rate of the skin test varieties required by the instructions was significantly higher than that of the varieties not mentioned (P ＜ 0.05). There were 48 cases of cephalosporin-related ADRs, with an incidence of 0.13%. The incidence of ADRs of varieties requiring skin test was significantly lower than that of varieties without skin test (P ＜ 0.05). By economic comparison, the total expenditure of skin test was 2 052 321.75 yuan, while the allergic reaction cost reduced by skin test was 1 107 963.12 yuan, which was significantly higher than the allergic reaction cost reduced by skin test, among which, Cefperazone-Sulbactam, Cefuroxime, Cefoperazone Tazobactam, Ceftazidime and so on were more obvious. Conclusion The cost of cephalosporin skin test is very high, while the positive rate of skin test is very low. Medical institutions can gradually reduce cephalosporin skin test under the premise of safe medication, reduce costs, and promote the rational use of cephalosporin in clinical practice.
|
|
|
|
|
|
[1] Khan DA，Banerji A，Bernstein JA，et al. Cephalosporin allergy：current understanding and future challenges [J]. J Allergy Clin Immunol Pract，2019，7（7）：2105-2114.
[2] Romano A，Valluzzi RL，Caruso C，et al. Evaluating immediate reactions to cephalosporins：time is of the essence [J]. J Allergy Clin Immunol Pract，2021，9（4）：1648-1657.e1. https：//doi.org/10.1016/j.jaip.2020.11.032.
[3] Alharbi HA. Antibiotic Skin Testing in the Intensive Care Unit：A Systematic Review [J]. Critical Care Nurse，2019， 39（6）：e1-e9.
[4] 中华人民共和国药典临床用药须知[M].北京：中国医药科技出版社，2017：650-653.
[5] 抗菌药物临床应用指导原则[M].北京：北京人民卫生出版社，2015：22-38．
[6] 陈新谦，金有豫，汤光.新编药物学[M].北京：人民卫生出版社，2018：47-49．
[7] 国家卫生健康委员会.国家卫生健康委医政医管局关于征求β内酰胺类抗生素皮肤试验指导原则（2020年版）（征求意见稿）意见的函[S].国卫医医疗便函，2020（122号）：1-15.
[8] 韩梅，宋志勇，刘海净.基于药品说明书分析头孢菌素类抗菌药物皮肤过敏试验[J].中国药房，2013，24（22）：2098-2100.
[9] 张思娟.头孢菌素类致过敏反应的观察及护理[J].吉林医学，2015，36（6）：1245.
[10] Gonzalez-Estrada A，Radojicic C. Penicillin allergy：A practical guide for clinicians [J]. Cleve Clin J Med，2015，82（5）：295-300.
[11] Yang MS，Kang DY，Seo B，et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins； a large multicenter retrospective cohort study [J]. Allergy，2018，73（9）：1833-1841.
[12] Chan SL，Ng HY，Sung C，et al. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults [J]. Pharmacogenomics，2019，19（4）：401-410.
[13] Zheng ZQ，Jiang C，Yu RL，et al. General characteristics，economic burden，causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China [J]. J Clin Pharm Ther，2020，45（5）：1087-1097.
[14] 张丽霄，杨翠翠，付俊涛，等.我院头孢菌素类注射剂皮试费用的经济学分析[J].中国药房，2017，28（14）：1884-1888.
[15] Kwon JW，Kim YJ，Yang MS，et al. Results of Intradermal Skin Testing with Cefazolin according to a History of Hypersensitivity to Antibiotics [J]. J Korean Med Sci，2019， 34（50）：e319.
[16] 黄祖明，李文胜，何行玲，等.头孢菌素类药物皮试方法的探讨[J].中国药房，2006，17（17）：1353-1355.
[17] Choi JH. Does Cephalosporin Skin Test Predict Immediate Hypersensitivity to Cephalosporin? [J]. J Korean Med Sci，2019，34（50）：e328.
[18] Lundkvist J，Jonsson B. Pharmacoeconomics of adverse drug reactions [J]. Fundam Clin Pharmacol，2004，18（3）：275-280.
[19] 秦侃，范鲁雁，赵林海.1585例药品不良反应的费用测算和分析[J].药物流行病学杂志，2009，18（4）：268-270.
[20] Vaismoradi M，Logan PA，Jordan S，et al. Adverse drug reactions in Norway：a systematic review [J]. Pharmacy，2019，7（3）：E102.
[21] Al Damen L，Basheti I. Preventability analysis of adverse drug reactions in a Jordanian hospital：a prospective observational study [J]. Int J Clin Pharm，2019，41（6）：1599-1610.
[22] 栾嵘，朱婧，翟所迪.基于化学结构分析头孢曲松的皮肤试验问题[J].药物不良反应杂志，2014，16（2）：68-70.
[23] 李洪莲.浅谈头孢菌素类药物在临床应用中的过敏反应[J].中国实用医药，2012，7（4）：150-151.
[24] 赵红梅，胡睿婷.头孢菌素类药物与其他药物联用导致不良反应的情况[J].中国当代医药，2019，26（21）：184-186.
[25] 吴仲玉，刘兆云.我院头孢菌素类抗菌药物合理使用及皮试情况分析[J].中国医药科学，2020，10（16）：54-57.
[26] 陈冠容.头孢菌素类抗生素过敏反应与产品质量的关系[J].中国医院药学杂志，2009，29（1）：66-67.
[27] 张筱璇，汤智慧，朱曼，等.国内部分医院β-内酰胺类抗生素皮肤试验现状调查分析[J].药物流行病学杂志，2018，27（1）：33-37. |
|
|
|
